FY2025 · period end Dec '25 · from the 10-K filed Feb 17, 2026
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Revenue | $3.07B | $2.89B | $2.95B | $2.89B | $2.83B |
| Gross Profit | $1.10B | $1.00B | $1.13B | $1.14B | $1.18B |
| Operating Income | $0.58B | $0.57B | $0.68B | $0.73B | $0.75B |
| Net Income | $0.49B | $0.49B | $0.59B | $0.59B | $0.66B |
| EPS (Diluted) | $6.79 | $6.69 | $7.88 | $7.73 | $8.67 |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Total Assets | $4.27B | $3.64B | $3.83B | $3.62B | $3.31B |
| Total Liabilities | $1.09B | $0.96B | $0.95B | $0.93B | $0.98B |
| Stockholders' Equity | $3.18B | $2.68B | $2.88B | $2.68B | $2.34B |
| Cash & Equivalents | $0.79B | $0.48B | $0.85B | $0.89B | $0.76B |
| Total Debt | — | — | — | — | — |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Operating Cash Flow | $0.75B | $0.65B | $0.78B | $0.72B | $0.58B |
| Capital Expenditures | $0.29B | $0.38B | $0.36B | $0.28B | $0.25B |
| Free Cash Flow | $0.47B | $0.28B | $0.41B | $0.44B | $0.33B |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Gross Margin | 35.9% | 34.5% | 38.3% | 39.4% | 41.5% |
| Operating Margin | 0.2% | 0.2% | 0.2% | 0.3% | 26.6% |
| Net Margin | 0.2% | 0.2% | 0.2% | 0.2% | 23.4% |
| Return on Equity | 16.9% | 17.7% | 21.3% | 23.3% | 28.3% |
| Return on Assets | 12.5% | 13.2% | 15.9% | 16.9% | 20.0% |
| Debt / Equity | 0.06× | 0.08× | 0.07× | 0.08× | — |
Showing the most recent 5 annual periods. Get 15 years of history on the Pro plan, or unlimited history back to 1993 plus the smart-money dataset and webhooks on Institutional.
| Form | Accession ID | Report Date | Filing Date | Accepted At | Source |
|---|---|---|---|---|---|
| 8-K | 0000105770-26-000097 | Jul 23, 2026 | Jul 23, 2026 | Jul 23, 2026 11:14 UTC | EDGAR |
| 10-Q | 0000105770-26-000099 | Jun 30, 2026 | Jul 23, 2026 | Jul 23, 2026 20:15 UTC | EDGAR |
| 8-K | 0000105770-26-000093 | Jul 14, 2026 | Jul 14, 2026 | Jul 14, 2026 20:29 UTC | EDGAR |
| 8-K | 0000105770-26-000080 | May 31, 2026 | Jun 1, 2026 | Jun 1, 2026 20:32 UTC | EDGAR |
| 8-K | 0000105770-26-000068 | May 7, 2026 | May 11, 2026 | May 11, 2026 21:06 UTC | EDGAR |
| 8-K | 0000105770-26-000056 | May 4, 2026 | May 5, 2026 | May 5, 2026 20:49 UTC | EDGAR |
| 8-K | 0000105770-26-000047 | Apr 23, 2026 | Apr 23, 2026 | Apr 23, 2026 11:11 UTC | EDGAR |
| 10-Q | 0000105770-26-000049 | Mar 31, 2026 | Apr 23, 2026 | Apr 23, 2026 20:12 UTC | EDGAR |
Direct links to SEC EDGAR. WST has additional filings available on the SEC site.
6 numbers WEST PHARMACEUTICAL SERVICES INC later changed — same XBRL tag, both filings linked.
Operating Income (Loss)·Q2 2017
Minor restatementwas$42.7M
Revised down in a 10-Q.
Operating Income (Loss)·Q3 2017
Minor restatementwas$63.9M
Revised down in a 10-Q.
Operating Income (Loss)·FY 2017
Minor restatementwas$228.9M
Revised down in a 10-K.
Operating Income (Loss)·Q1 2017
Minor restatementwas$61.3M
Revised down in a 10-Q.
Operating Income (Loss)·FY 2016
Minor restatementwas$196.8M
Revised down in a 10-K.
Other Sundry Liabilities, Current·As of Dec 31, 2014
Major restatementwas$16.1M
Revised down in a 10-K.
WST is not the only one.
See every restatement we've found across the market — or get an alert the next time WST revises a number.
Restatements are detected by comparing every vintage of a fact across all of WEST PHARMACEUTICAL SERVICES INC's filings back to 1993. A revision is not by itself a sign of wrongdoing — companies re-file for many legitimate reasons. This list is not exhaustive: it shows WST's most significant revisions, and a figure absent from it has not been certified as unrevised.
Who is buying and selling WEST PHARMACEUTICAL SERVICES INC — insider transactions from Forms 3/4/5/144 and institutional ownership from 13F, 13D, and 13G filings, point-in-time stamped like every other fact in the library. Traders read it as a positioning signal; risk desks read it as concentration.
No published research on WST yet.
Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows, every figure pinned to its SEC filing. Be the first: run equity_research_brief on WST and publish the result to your public profile.
Ask about WEST PHARMACEUTICAL SERVICES INC
Continue in Workspace — cited answers on WST, a thesis you can score, or a signal on the next filing.
Open in WorkspaceGet 15 years of data
Quarterly and annual financials back to 2011 on Pro (1993 on Institutional). Point-in-time accurate with zero survivorship bias.
View plansQuery via Python SDK
Pull data into DuckDB with 3 lines of Python. Works in Jupyter notebooks, scripts, and CI pipelines.
SDK docsConnect via MCP Server
Wire Claude, Cursor, or Codex directly to live SEC data with a single Bearer token. No scraping, no glue code.
MCP docs